fbpx
  • Home
  • Study Details
Not currently enrolling

A Clinical Research Study Looking at the Safety and Effectiveness of a New Anti-viral, EIDD-2801, to Limit the Amount of Infectious SARS-CoV-2 Virus in People Who Test Positive for COVID-19

The purpose of this research is to find out if the study drug, EIDD-2801, can help people recover from coronavirus disease 2019 (COVID-19), as well as limit the spread of COVID-19 between people. EIDD-2801 is an experimental treatment not approved by the U.S. Food and Drug Administration (FDA).

Age & Gender

  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive

Contact the Team

Location

Thank you for your interest, but this study is not currently enrolling.

North Carolina (Alamance, Chatham, Durham, Franklin, Granville, Harnett, Johnston, Lee, Nash, Orange, Wake, Wilson)

Additional Study Information

Principal Investigator

William Fischer
Medicine-Infectious Diseases

Study Type

Clinical or Medical
Interventional

Study Topics

Immune System/Infections
COVID-19

IRB Number

20-1692

ClinicalTrials.gov

NCT04405570

logo for the North Carolina Translational and Clinical Sciences Institute
logo for UNC Health
logo for UNC School of Medicine
logo for UNC Research
Research for Me logo

Copyright © 2013-2020 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH.  This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Questions?

  • This email address is being protected from spambots. You need JavaScript enabled to view it.